Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2143079 | Lung Cancer | 2009 | 4 Pages |
Abstract
In our study, the oldest age group represented a small percentage of all patients included in clinical and pharmacogenetic trials. Although this might indicate bias when interpreting the results, age is not a contraindication to the treatment of the “fit” elderly. Patients with good performance status can be treated with standard doublets. We believe that special attention should be paid to cases with high risk of neutropenia. Research in this population should now be aimed at finding more selective treatments, based on the genetic differences that older patients have.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mariano Provencio, Carlos Camps, Vicente Alberola, Bertomeu Massutti, Nuria Viñolas, Dolores Isla, Manuel Dómine, Isabel Millán, Manuel Cobo, Rafael Rosell,